340B Drug Discount Program Garners AG Concern and Recommendations

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • A bipartisan coalition of 23 AGs (21 Democrats and 2 Republicans) sent a letter in response to a request for information issued by a bipartisan group of U.S. Senators to strengthen the 340B Drug Pricing Program, which requires drug manufacturers participating in Medicaid and Medicare to provide discounted drugs to covered entities that serve financially vulnerable patients.
  • The AGs assert in their letter that drug manufacturers are increasingly imposing potentially unlawful restrictions on 340B entities, such as restricting entities’ ability to utilize retail community pharmacies or mail order pharmacies, commonly known as “contract pharmacies,” to dispense medications to their patients.
  • The AGs ask Congress to give the Health Resources Services Administration (HRSA), which oversees the 340B program, sufficient authority to promulgate regulations that would ensure 340B entities are able to utilize contract pharmacies to dispense drugs to patients.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide